EX-1 2 soleno_13ddec212018ex99.htm JOINT FILING AGREEMENT

Exhibit 1

 

 

JOINT FILING AGREEMENT

 

This Agreement will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on the date hereof with respect to the beneficial ownership by the undersigned of the Common Shares of Soleno Therapeutics Inc. is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below, in accordance with Rule 13d-1 under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

Dated as of December 27, 2018

 

   
  ABINGWORTH BIOVENTURES VII, LP  
     
  By: Abingworth LLP, its Manager  
     
     
  By: /s/ John Heard  
    Name:  John Heard  
    Title:    Authorized Signatory  
     
     
  Abingworth LLP  
     
     
  By: /s/ John Heard  
    Name:  John Heard  
    Title:    Authorized Signatory